Eli Lilly's board elects multinational financial leader

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Eli Lilly's board elects multinational financial leader

The board of directors at Eli Lilly ($LLY) has elected Jackson Tai as its newest member. Tai serves as a nonexecutive director of The Bank of China, Singapore Airlines, NYSE Euronext, MasterCard and Royal Philips NV. Lilly CEO John Lechleiter said in a statement: "Mr. Tai brings to the Lilly board extensive experience in international business and finance, including serving as the CEO of a major multinational financial institution and as a board member of several leading global companies. Having lived and worked in Japan and Singapore for almost 15 years, Jack has a deep understanding of the Asia-Pacific region that will be particularly helpful as our business in Asia continues to grow." Release

Eli Lilly
Jackson Tai joined the board of directors.


Shire Pharmaceuticals
Dominic Blakemore was elected to the board of directors.


Biotech

Dr. Laurie Smaldone Alsup, chief scientific officer at PharmApprove, has been elected to KaloBios Pharmaceuticals' ($KBIO) board of directors. Release

Drs. Benjamin Carson and Jan Vermorken have joined the medical advisory board of Vaccinogen. Release

OvaScience ($OVAS) has appointed Dr. Hugh Taylor to the company's scientific advisory board. Taylor is the Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences; professor of molecular, cellular and developmental biology at the Yale School of Medicine; and chief of obstetrics and gynecology at Yale-New Haven Hospital. Release

Five Prime Therapeutics ($FPRX) has appointed Aron Knickerbocker, senior vice president and chief business officer of Five Prime, to the company's board of directors and Marc Belsky to the position of chief financial officer. Belsky and Knickerbocker both joined the company in 2009. Release

Immune Design has appointed Dr. Frank Hsu as vice president, head of oncology. Hsu recently served as chief medical officer for Zyngenia. Release

Celsus Therapeutics has appointed Dr. Pablo Jimenez to the position of chief medical officer. Jimenez previously held various positions at Novartis ($NVS). Release

Harvard Bioscience appointed Yoav Sibony as its vice president of global sales. Release

BioDelivery Sciences ($BDSI) brought on Ernest De Paolantonio as its chief financial officer. De Paolantonio previously served as CFO of CorePharma. Release

Bruin Biometrics appointed Jeff Greiner and Eve Kurtin to its board of directors. Release

Dan Calvo took the helm as CEO of Gyros AB, replacing Erik Walldén, who stepped down. Release

PATH appointed Ashley Birkett as director of its Malaria Vaccine Initiative. Birkett was most recently the program's deputy director. Release

Pharma

>  Mallinckrodt ($MNK) has made three new appointments to its senior management team: Hugh O'Neill will serve as senior vice president and president of specialty pharmaceuticals; Gary Phillips will be senior vice president and chief strategy officer; and Mario Saltarelli has joined as senior vice president and chief science officer. Release

Daniel Swisher, CEO of Sunesis Pharmaceuticals ($SNSS), joined Cerus' board of directors. Release

Dominic Blakemore joined Shire's ($SHPG) board of directors. Previously, Blakemore was CFO at Iglo Foods Group and Finance & Strategy Director at Cadbury. Release

Medical Devices

Dr. George Lopez is stepping down from the position of president and CEO of ICU Medical. Steven Riggs, vice president of operations, will step in as acting CEO. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.